May Wang
Corporate Officer/Principal presso HUTCHMED (CHINA) LIMITED
Profilo
Qing Mei Wang is currently working as the SVP-Business Development & Strategic Alliances at HUTCHMED (China) Ltd.
since 2010 and at Hutchison MediPharma Ltd.
since 2012.
Previously, Dr. Wang worked as the Head-Asia Discovery Biology at Eli Lilly & Co. Dr. Wang holds a doctorate degree from Purdue University.
Posizioni attive di May Wang
| Società | Posizione | Inizio |
|---|---|---|
| HUTCHMED (CHINA) LIMITED | Corporate Officer/Principal | 01/01/2010 |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 27/07/2011 |
Precedenti posizioni note di May Wang
| Società | Posizione | Fine |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Formazione di May Wang
| Purdue University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| HUTCHMED (CHINA) LIMITED | Health Technology |
| Aziende private | 1 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
- Borsa valori
- Insiders
- May Wang
